Biologics, including cell and gene therapies, have become a hot topic in the pharmaceutical industry as their therapeutic applications expand. Challenges of developing biologic drug products include scale-up for commercial manufacturing and production at a high enough purity for effective medical applications. Thus, it is critical to examine the biomanufacturing steps that produce biologic drug products in order to optimize the process for the necessary production scale without losing quality and purity.
Read Our Recent Blogs
Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider
Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider
Integrating the well-respected and trusted Agilis brand and team extends Kymanox’s capabilities in human factors (HF) by adding incredible talent, the ability to conduct HF stu...
Investment Reports Interview with Stephen M. Perry, CEO and Founder of Kymanox
Kymanox CEO and Founder, Stephen M. Perry was interviewed as part of the Investment Reports article, The New Era of Life Sciences 2023, published on 17MAR23,
What were the circumstances that brought Kymanox to life and what does your present foo...
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...